Fu Haiying, Shi Songsheng, Chen Lusan, Xu Benhua, Huang Wanling, Chen Yi, Wu Xuejing, Shen Jianzhen, Liu Tingbo
Department of Haematology, Fujian Medical University Union Hospital, Fujian Institute of Haematology, Fujian Medical Centre of Haematology, Fujian Provincial Key Laboratory on Haematology, Fuzhou, Fujian Province, China.
Department of Neurosurgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
J Int Med Res. 2021 Apr;49(4):300060521999533. doi: 10.1177/0300060521999533.
Primary central nervous system Hodgkin's lymphoma (CNS-HL) is extremely rare. This current case report describes a 60-year-old male patient that presented with numbness of the left lower extremity and worsening headache. After a full range of investigations and a partial resection of the right cerebellum, external ventricular drainage reservoir placement and cranioplasty, he was diagnosed with primary CNS-HL. The patient was treated with 3 g/m methotrexate (intravenous [i.v.], once a day, day 1) and 1 g/m cytarabine (i.v., every 12 h, days 2 + 3), followed by anti-programmed cell death protein 1 antibodies (200 mg sintilimab, i.v., once a day, day 1, every 3 weeks). After six courses of treatment with intrathecal injections of 50 mg cytarabine (once a day, day 1) and 5 mg dexamethasone (once a day, day 1), there was no residual lesion on cranial magnetic resonance imaging. No significant drug-related adverse events were observed. The patient has been followed up every 3 months and no relapse has occurred.
原发性中枢神经系统霍奇金淋巴瘤（CNS-HL）极为罕见。本病例报告描述了一名60岁男性患者，其出现左下肢麻木和头痛加重症状。经过全面检查以及右小脑部分切除术、外置脑室引流储液器置入术和颅骨成形术后，他被诊断为原发性CNS-HL。该患者接受了3 g/m²甲氨蝶呤（静脉注射，每日1次，第1天）和1 g/m²阿糖胞苷（静脉注射，每12小时1次，第2天和第3天）治疗，随后使用抗程序性细胞死亡蛋白1抗体（200 mg信迪利单抗，静脉注射，每日1次，第1天，每3周1次）。在鞘内注射50 mg阿糖胞苷（每日1次，第1天）和5 mg地塞米松（每日1次，第1天）进行六个疗程的治疗后，头颅磁共振成像未发现残留病灶。未观察到明显的药物相关不良事件。该患者每3个月进行随访，未发生复发。
